about
sameAs
Vitamin D supplementation and breast cancer prevention: a systematic review and meta-analysis of randomized clinical trialsParenteral anticoagulation in ambulatory patients with cancerAnticoagulation for people with cancer and central venous cathetersLow molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancerAnticoagulation for the initial treatment of venous thromboembolism in patients with cancerOral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulationAnticoagulation for the long-term treatment of venous thromboembolism in patients with cancerOral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulationAnticoagulation for the initial treatment of venous thromboembolism in patients with cancerParenteral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulationLow molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancerParenteral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulationAnticoagulation for the initial treatment of venous thromboembolism in patients with cancerAnticoagulation for patients with cancer and central venous cathetersOral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulationAnticoagulation for the initial treatment of venous thromboembolism in patients with cancerOral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulationAnticoagulation for the long-term treatment of venous thromboembolism in patients with cancerAnticoagulation for patients with cancer and central venous cathetersAnticoagulation for the initial treatment of venous thromboembolism in patients with cancerAnticoagulation for the long term treatment of venous thromboembolism in patients with cancerAnticoagulation for thrombosis prophylaxis in cancer patients with central venous cathetersParenteral anticoagulation for prolonging survival in patients with cancer who have no other indication for anticoagulationOral anticoagulation for prolonging survival in patients with cancerLifetime total and beverage specific--alcohol intake and prostate cancer risk: a case-control studyThromboprophylaxis for patients with cancer and central venous catheters: a systematic review and a meta-analysis.Low-molecular-weight heparin vs unfractionated heparin for perioperative thromboprophylaxis in patients with cancer: a systematic review and meta-analysis.Low-molecular-weight heparins are superior to vitamin K antagonists for the long term treatment of venous thromboembolism in patients with cancer: a cochrane systematic reviewAnticoagulation for the initial treatment of venous thromboembolism in patients with cancer: a systematic review.An instrument to assess quality of life in relation to nutrition: item generation, item reduction and initial validationOutcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study.Molecular profiles of screen detected vs. symptomatic breast cancer and their impact on survival: results from a clinical series.The Hippo transducer TAZ as a biomarker of pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy.Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer.p53 status as effect modifier of the association between pre-treatment fasting glucose and breast cancer outcomes in non diabetic, HER2 positive patients treated with trastuzumab.Efficacy of chemotherapy in metastatic male breast cancer patients: a retrospective study.Role of gonadotropin-releasing hormone analogues in metastatic male breast cancer: results from a pooled analysisDNA Damage and Repair Biomarkers in Cervical Cancer Patients Treated with Neoadjuvant Chemotherapy: An Exploratory Analysis.Fasting glucose and treatment outcome in breast and colorectal cancer patients treated with targeted agents: results from a historic cohort.Body mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer.
P50
Q21089763-D274A4D9-4033-4A6D-8B8D-812278A06C4DQ22252972-673F4766-D2F6-4BC2-BD1F-C196A38476D1Q24193103-C7BAFB34-F504-42A2-9CA6-17D6B83CC354Q24193749-B567E42D-A41F-4A41-B52E-797EC39E2C0FQ24193871-FDBCBD32-E614-4083-B7AF-7B41872EB23FQ24194116-3B59D563-7F44-42A3-99A0-D0060F1220DDQ24194904-1D664D0B-8F2F-4B6B-B377-27701EFC1C71Q24194926-FCEB8800-0DC3-4F4B-9637-D4A78F44970FQ24234155-6283DB0F-BE50-4371-8C70-5FFF4BC57D11Q24234857-82E82C47-3C1B-405E-A374-161D53E24C13Q24235023-46DC7EE1-11CF-4230-BFA9-CC2B1992EDAAQ24235112-B65F215A-0EB0-412B-9DEC-ABD305A50B02Q24235193-A3F6795F-3CBE-4BC3-AA6C-E4B3C6D977F1Q24235260-DFA3A6C0-6252-45A5-AA1B-2DDCB0B1545AQ24235785-FEEA4F8C-9A9C-4C08-BA9C-51F2406CF5C3Q24236443-1B083F9C-491C-43CC-B72E-C19D9D547F9AQ24236595-C0E0A2F4-4AD4-429A-900B-BE0683555AE4Q24236620-2516770E-3B7E-46EF-8C41-0FC438A1A135Q24236648-47880CBA-DF99-45B3-998A-4335A4F876FBQ24242243-5F808437-D5A7-4425-B847-2B00977973E3Q24243286-C500D403-AB56-47EC-B44E-ECA26201F5FAQ24244042-B4B991EE-C434-4E7A-8AAF-6DAE7C591F99Q24244310-1452F5E5-F672-4C04-A9A9-6F0CFEDFE6BFQ24245072-FFF59A01-332B-450B-AAD7-B721F280AEE9Q24799155-40A533B4-CF34-4DDF-9DF2-DC8CB41D3489Q33379238-BD83775C-A044-407E-8E6C-40F6F2D6F103Q33380057-44877867-010D-494E-86D5-4EB072B7566AQ33380411-F50B441D-8C8A-4F69-823D-C323F438FD6EQ33380863-49D310B7-9286-4498-8962-CBDEA86D47F9Q33761609-3CAC79B4-AEBF-414E-9530-EA698D88CF43Q34240305-B1BB724A-3533-41F1-ADFA-847220CF29D7Q34543733-6ADB18F3-18D4-42B1-884E-952C98D2563DQ34654520-AF4746F3-BA2B-4811-A2B1-81DDDB469C98Q34658209-9F572F2E-F7B3-49E5-B4B3-E23014573097Q34786457-A87EF2F5-C366-4A03-B107-C226CF05920CQ35367903-68F1FFA8-F2B9-489D-87F6-D0F888C3B809Q35633574-276C5F79-3875-4518-B8FE-014236CAC1E9Q35941085-241E7A74-9A42-4243-A73C-F8AA57FD9F75Q36071002-F2D9B5F0-F8B9-4F77-AB68-7D289379586DQ36272043-63D22D39-3FA5-42B8-AC99-3D2315D9A3F4
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Maddalena Barba
@ast
Maddalena Barba
@en
Maddalena Barba
@es
Maddalena Barba
@nl
Maddalena Barba
@sl
type
label
Maddalena Barba
@ast
Maddalena Barba
@en
Maddalena Barba
@es
Maddalena Barba
@nl
Maddalena Barba
@sl
prefLabel
Maddalena Barba
@ast
Maddalena Barba
@en
Maddalena Barba
@es
Maddalena Barba
@nl
Maddalena Barba
@sl
P106
P1153
23484518200
P21
P31
P496
0000-0001-9050-2917